Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Disaggregated Revenues by Timing of Transfer of Goods or Services

The following tables present our revenues disaggregated by timing of transfer of goods or services (in thousands):

	Three Months Ended September 30, 2019						Nine Months Ended September 30, 2019
	Product Revenue, net		Collaboration and License Revenue		Total		Product Revenue, net		Collaboration and License Revenue		Total
Timing of revenue recognition:
Transferred at a point in time	$	35,743	$	—	$	35,743	$	83,269	$	—	$	83,269
Transferred over time	—		1,056		1,056		—		4,123		4,123
Total	$	35,743	$	1,056	$	36,799	$	83,269	$	4,123	$	87,392

	Three Months Ended September 30, 2018						Nine Months Ended September 30, 2018
	Product Revenue, net		Collaboration and License Revenue		Total		Product Revenue, net		Collaboration and License Revenue		Total
Timing of revenue recognition:
Transferred at a point in time	$	7,176	$	—	$	7,176	$	10,047	$	—	$	10,047
Transferred over time	—		7,001		7,001		—		14,785		14,785
Total	$	7,176	$	7,001	$	14,177	$	10,047	$	14,785	$	24,832

Schedule of Net Product Revenues Disaggregated by Geographic Region

The following table presents our net product revenues disaggregated by geographic region (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
United States	$	32,968	$	7,176	$	80,494	$	10,047
Europe	2,775		—		2,775		—
Total revenues	$	35,743	$	7,176	$	83,269	$	10,047

Schedule of Changes in Contract Assets and Liabilities

The following table presents changes in our contract assets and liabilities for the nine months ended September 30, 2019 (in thousands):

	Balance at Beginning of Period		Addition		Deduction			Balance at End of Period
Contract assets:
Unbilled - collaboration and license revenue	$	9,880	$	3,461	$	(9,553	)	$	3,788
Total contract assets	$	9,880	$	3,461	$	(9,553	)	$	3,788
Contract liabilities:
Deferred revenue	$	6,335	$	1,402	$	(2,277	)	$	5,460
Total contract liabilities	$	6,335	$	1,402	$	(2,277	)	$	5,460

Significant changes in the contract liabilities balances during the period are as follows (in thousands):

	Three Months Ended as of September 30, 2019		Nine Months Ended September 30, 2019
Revenue recognized according to the current period performance that was included in the contract liability at the beginning of the period	$	47	$	662

Estimated Revenue Expected to be Recognized in Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of September 30, 2019 (in thousands):

Collaborator	Transaction Price Allocated to the Remaining Performance Obligation as of September 30, 2019		Expected Year By Which Revenue Recognition Will Be Completed	Percentage of Revenue Recognized
BMS and Pfizer - 2016 agreement	$	450	2021	96	%
Daiichi Sankyo - 2014 agreement	772		2020	98	%
Daiichi Sankyo - 2016 agreement	2,485		2023	84	%
Bayer - 2016 agreement	2,018		2023	87	%
Total	$	5,725